We are live on ! Find out more
NVS icon

Novartis

1,128 hedge funds and large institutions have $20.7B invested in Novartis in 2020 Q2 according to their latest regulatory filings, with 83 funds opening new positions, 408 increasing their positions, 421 reducing their positions, and 78 closing their positions.

New
Increased
Maintained
Reduced
Closed

88% more call options, than puts

Call options by funds: $203M | Put options by funds: $108M

6% more first-time investments, than exits

New positions opened: 83 | Existing positions closed: 78

2% more capital invested

Capital invested by funds: $20.4B → $20.7B (+$333M)

0.08% less ownership

Funds ownership: 9.71%9.63% (-0.08%)

0% less funds holding

Funds holding: 1,1331,128 (-5)

3% less repeat investments, than reductions

Existing positions increased: 408 | Existing positions reduced: 421

50% less funds holding in top 10

Funds holding in top 10: 3015 (-15)

Holders
1,128
Holders Change
-5
Holders Change %
-0.44%
% of All Funds
23.13%
Holding in Top 10
15
Holding in Top 10 Change
-15
Holding in Top 10 Change %
-50%
% of All Funds
0.31%
New
83
Increased
408
Reduced
421
Closed
78
Calls
$203M
Puts
$108M
Net Calls
+$95.1M
Net Calls Change
+$44.4M
Name Holding Trade Value Shares
Change
Change in
Stake
RG
151
Renaissance Group
Kentucky
$10M -$834K -9,664 -8%
RCYC
152
Richard C. Young & Co
Rhode Island
$9.99M -$200K -2,319 -2%
Ensign Peak Advisors
153
Ensign Peak Advisors
Utah
$9.96M +$3.33M +38,578 +51%
CIBC World Market
154
CIBC World Market
Ontario, Canada
$9.63M +$386K +4,473 +4%
FT
155
Fiduciary Trust
Massachusetts
$9.07M -$133K -1,543 -1%
CSIC
156
Clifford Swan Investment Counsel
California
$9M -$177K -2,054 -2%
TG
157
TCW Group
California
$8.88M -$613K -7,104 -7%
PNC
158
Park National Corp
Ohio
$8.84M -$2.02M -23,422 -19%
PGFC
159
Peapack-Gladstone Financial Corp
New Jersey
$8.75M +$1M +11,622 +13%
RG
160
Rathbones Group
United Kingdom
$8.71M -$27.8K -322 -0.3%
CT
161
Cambridge Trust
Massachusetts
$8.67M +$212K +2,455 +2%
OA
162
Oxbow Advisors
Texas
$8.66M +$8.56M +99,140 New
GF
163
Gabelli Funds
New York
$8.65M
MJP
164
Michael J. Puzo
$8.63M -$34.4K -398 -0.4%
ECM
165
ETrade Capital Management
Virginia
$8.48M +$1.18M +13,669 +16%
Federated Hermes
166
Federated Hermes
Pennsylvania
$8.38M -$2.35M -27,206 -22%
BCM
167
Buckhead Capital Management
Georgia
$8.27M +$48.2K +558 +0.6%
TTWM
168
TCV Trust & Wealth Management
Virginia
$8.22M +$329K +3,814 +4%
AAIM
169
American Assets Investment Management
California
$8.18M -$1.29M -15,000 -14%
LG
170
LaFleur & Godfrey
Michigan
$8.14M -$499K -5,784 -6%
Carson Wealth (CWM LLC)
171
Carson Wealth (CWM LLC)
Nebraska
$8.08M
Fifth Third Bancorp
172
Fifth Third Bancorp
Ohio
$7.83M +$3.63K +42 +0%
NCM
173
Narwhal Capital Management
Georgia
$7.79M +$518K +5,997 +7%
GIM
174
Grassi Investment Management
California
$7.74M +$132K +1,525 +2%
CTA
175
Carillon Tower Advisers
Florida
$7.66M +$52.1K +603 +0.7%

NVS Hedge Fund Activity: Q2 2020 in Review

1,128 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q2 2020, worth a combined $20.7B — up 1.6% from $20.4B a quarter earlier.

Buyers outnumbered sellers: 83 funds opened new NVS positions and 78 closed out — a net gain of 5 holders — while 408 added to existing stakes and 421 trimmed.

The largest buyer was Boston Partners, adding an estimated $290M. The largest seller was Dodge & Cox, cutting an estimated $310M.

  • 1,128 institutional investors held Novartis (NVS) as of Q2 2020, down from 1,133 in Q1 2020.
  • Funds reported $20.7B of Novartis stock for Q2 2020, up 1.6% quarter-over-quarter.
  • 83 funds opened new Novartis positions in Q2 2020 and 78 closed out, a net change of +5 holders.
  • The largest Novartis buyer in Q2 2020 was Boston Partners, an estimated $290M added.
  • The largest Novartis seller in Q2 2020 was Dodge & Cox, an estimated $310M sold.

Based on aggregated 13F filings for Q2 2020.